Josh Davis (@gurujosh) Bsky

Same. But even when you subtract the bots and all the noisy rubbish, X still has more going on! I've been following both for #ESCMIDGlobal2026 posts

1 day ago 1 0 0 0

David Paterson at #ESCMIDGlobal2026 Highlights important issue of generic versus brand name meropenem – previous work has suggested chemical differences, harder to dissolve and even higher mortality with generic preparations

2 days ago 11 5 3 1

Mical Paul discussing whether to stop and publish now (after what is effectively an interim analysis) or continue to ~1,000 patients for the mortakity endpoint D’oh! - you just published!!

2 days ago 0 0 0 0

Fantastic trial, congrats Brett! (@1healthau.bsky.social). This should have been in the big Trial Run session!!

2 days ago 2 0 0 0

Annelies Zinkernagel at #ESCMIDGlobal2026 TIGRIS, ANDROMEDA-2, ImmunoSep trials show that the era of precision medicine in #Sepsis management has arrived

2 days ago 2 0 0 0

New target trial emulation study in @cmijournal.bsky.social comparing monotherapy (mostly amp) to combo (mostly amp with CRO or gent) for Enterococcus faecalis BSI (not endocarditis).

Composite outcome similar between mono & combo

#IDSky

www.clinicalmicrobiologyandinfection.org/article/S119...

1 month ago 9 4 1 0

More than a message: Death by a 1,000 “Chats” Abstract. Secure electronic messaging within the electronic health record (EHR), such as Epic Chat, has transformed communication in hospitals by enabling

Check out our article and guidance on Epic chat messages in CID. Anyone doing frontline clinical work understands the substantial downsides of constant, on-demand, text communication in the EHR. So great to write this with ID fellows. doi.org/10.1093/cid/...

2 months ago 28 11 1 1

Oh nooo! NSW is about to switch to Epic. Any tips on how it works with ID consults welcome!

2 months ago 1 0 1 0

My top 10 ID papers for 2025. Full citations and descriptions available at clarityinitiative.org/hot-takes

Also see/hear our Communicable podcast episode on this at communicable.transistor.fm/episodes/com...

What were your top 10? Any thoughts about what I missed welcome!

#IDSky #Top10papers

2 months ago 31 9 1 1

📣 New #Communicable drops Mon 26 Jan! In our last episode, we brought you some favorite #clinmicro papers of 2025. We continue this thread in our next episode with top ID papers of 2025, picked by our editors, Josh Davis & Emily McDonald and guest, Steven Tong. ⭐ Tune in Monday🎙️

#IDSky

3 months ago 8 5 0 1

It's not syndromic surveillance. It's swabbing every week regardless of symptoms. We also ran metagenomics on those with symptoms but no virus detected - found some interesting things (future paper). We hope to get this funded as an ongoing sentinel surveillance system.

3 months ago 1 0 0 0

How Do We Win? The GAME CHANGER Trial Erin K. McCreary, PharmD (1), Ahmad Mourad, MD MHS (2, 3)

The 3rd and 4th commentaries on recent ID trials are up on the CLARITY website (we aim to publish in depth reviews of important ID stuies).

This time looking at the GAMECHANGER trial:
clarityinitiative.org/commentaries...

@erinmccreary.bsky.social with Ahmad Mourad

@gurujosh.bsky.social

#IDSky

3 months ago 13 5 0 0

The Pandemic Respiratory Virus Epidemiological Surveillance Trial - A Self-swab Surveillance System for Respiratory Viruses Nested Within FluTracking PREVENT aimed to evaluate the feasibility of a community self-swab respiratory surveillance system embedded within the FluTracking Australia Framework. Hig

What viruses are up your nose? We asked 50 volunteers to swab their noses every week for a year to find out
#flutracking #COVID #rhinovirus #IDSky
academic.oup.com/jid/advance-...

3 months ago 26 9 1 1

Congratulations to the RSI trial team #CCRdownunder

4 months ago 4 2 2 0

Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery ABSTRACTSubcutaneous delivery of antibiotics is a practical alternative to intravenous administration. Ceftriaxone is commonly used for a variety of infections with limited data on the safety and pharmacokinetics of a 2 g subcutaneous dose. This was a prospective, self-controlled cross-over study in 20 stable inpatients receiving ceftriaxone for their infection. Following an intravenous dose, participants received a single dose of 2 g subcutaneous ceftriaxone, in 50 mL normal saline via gravity feed. Capillary dried blood spots were collected at baseline, 1, 2, 4, 8, and 24 hours following the subcutaneous and intravenous doses. Pain scores and infusion site reactions (edema/erythema) were assessed. Ceftriaxone concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay. A population pharmacokinetic model was developed using nonlinear mixed-effects modeling. The highest median (interquartile range) pain score within the first 2 hours following infusion of a subcutaneous dose of 2 g ceftriaxone was 2.5 (1–4). All participants were pain-free 4 hours after the infusion. The estimated bioavailability was 95.7% (95% bootstrap interval 90.3–99.5). Compared with intravenous, subcutaneous administration resulted in lower peak and comparable trough concentrations. The probability of target attainment for free drug concentrations was similar to intravenous administration for most common infections in hospitalized patients. Subcutaneous administration of 2 g ceftriaxone is well tolerated and has a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.IMPORTANCEThis prospective, self-controlled cross-over design study demonstrates that subcutaneous administration of 2 g ceftriaxone appears safe and well tolerated with a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.CLINICAL TRIALSThis study was registered at ACTRN12624000692538.

Study of 20 pts showed 2g SC ceftriaxone had 95.7% bioavailability, lower peak but similar trough vs IV; pain score max 2.5, pain-free by 4h; safe & well tolerated.💉🦠

#idsky

4 months ago 1 1 0 0

The CLARITY initiative: Clinical Literature Appraisal and Research education in InfecTious diseases and microbiologY Over the past two decades, the generation and application of clinical evidence in the fields of clinical infectious diseases and microbiology have entered a new era: one in which clinical guidelines a...

📣 We're thrilled to be part of #CLARITY, an initiative led by Josh Davis @gurujosh.bsky.social & @steventong.bsky.social for physicians, pharmacists & #clinmicro specialists passionate about #clinicalresearch & #evidence appraisal.
Join us! 🌱

#IDSky #MedSky #MedEd

www.cmi-comms.org/article/S295...

4 months ago 10 3 1 1

Parliament just passed into law the independent Australian Centre for Disease Control 🎉
The interim CDC will now move from under the Department of Health, Ageing, and Disability to an independent entity as of 1 Jan 2026!

#auspol #idepi #episky #medsky #idsky

5 months ago 9 2 0 0

#IDSky #PedsID

5 months ago 8 2 0 0

Great to speak with @thelancetinfdis.bsky.social together with @gurujosh.bsky.social about adaptive platform trials in infectious diseases!

5 months ago 13 8 1 0

Sorry dud link. See reply

5 months ago 1 0 0 0

How long do labs need to incubate #PJI specimens for? Clinicians and some guidelines want long (10-14 days) BUT with modern media and processes, this is probably not needed. See our new paper here sciencedirect.com/science/articl…
@#IDSky

6 months ago 9 0 2 0

Big congrats Amy and Richie!

7 months ago 1 0 0 0

Let me know if your fellows have any questions for the authors!

9 months ago 3 0 0 0

Thrilled to share our new research led by Jane Davies @menziesresearch.bsky.social on First Nations people in the NT living with chronic hepatitis B. An important study that could inform better care:

doi.org/10.1186/s128...

#idsky #MedSky #HepSky #LiverSky

9 months ago 6 4 2 0

Making sense of hierarchical composite endpoints in randomized clinical trials – a primer for infectious disease clinicians and researchers Hierarchical composite endpoints (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader,

Our review on hierarchical composite endpoints (HCEs) has just been published in @cidjournal.bsky.social:
doi.org/10.1093/cid/...

We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods.

@steventong.bsky.social @gurujosh.bsky.social

10 months ago 11 4 1 0

Communicable E28: Late-breaker trials at ESCMID Global: Should they change your practice? - part 2 Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald...

🎙️ Just published a new #Communicable episode: Communicable E28: Late-breaker trials at ESCMID Global: Should they change ...

Hosted by Josh Davis @gurujosh.bsky.social
Erin McCreary @erinmccreary.bsky.social
Emily McDonald @dremilymcd.bsky.social

Listen here:

#IDSky #Clinmicro #MedSky

10 months ago 14 8 0 1

Communicable E27: Late-breaker trials at ESCMID Global: Should they change your practice? - part 1 This episode of Communicable takes on a special format where editors of...

🎙️ Just published a new #Communicable episode: Communicable E27: Late-breaker trials...

Hosted by Marc Bonten @marcbonten.bsky.social
Josh Davis @gurujosh.bsky.social
Erin McCreary @erinmccreary.bsky.social
Emily McDonald @dremilymcd.bsky.social

Listen here:

#IDSky #Clinmicro #MedSky

11 months ago 12 8 0 1

⏰ Tune in Monday for the latest #Communicable and hear the complete discussion w/ our editors on some of the late breaker trials at #ESCMIDGlobal '25, part 1! 🎙️

@gurujosh.bsky.social @dremilymcd.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @escmid.bsky.social

#IDSky #clinmicro

11 months ago 12 4 1 2

Has been great interacting with >850 orthopods and ID doctors from >50 countries at the www.icmortho.com meeting. Lots of interest in the #ROADMAPtrial!

11 months ago 5 0 0 0

Posts by Josh Davis